MindMaze Therapeutics Holding SA officially emerged as a new entity following its merger with NeuroX Group SA, as announced on December 15, 2025. This business combination aims to enhance the delivery of evidence-based, precision digital treatments for neurological diseases. The newly formed company integrates neurotherapeutics, pharmacological treatments, and advanced technology, establishing a comprehensive approach to neurological care.
The merger was finalized after a definitive business combination agreement was signed in October 2025, with shareholder approval secured during an extraordinary general meeting in November. The combined entity is now positioned to redefine approaches to neurological care, addressing a pressing need as neurological diseases become one of the leading causes of disability worldwide.
Olaf Blanke, a member of the Board of Directors and a prominent figure in neuroscience, emphasized the urgency of addressing neurological conditions. He stated, “The situation is worsening due to aging populations, with 1 in 6 people expected to develop a neurological disease.” This statistic underscores the critical need for scalable and effective solutions, as traditional healthcare systems often struggle to provide adequate therapy.
MindMaze Therapeutics aims to bridge this gap by offering clinically validated neurotherapeutics that support patients throughout their recovery, from hospital to rehabilitation centers and into their homes. The company’s innovative platform combines digital and pharmacological treatments, enabling more effective interventions for a variety of neurological conditions.
Walid Hanna, Chairman of the Board of Directors of MindMaze Therapeutics, remarked on this transformative moment for the company. “Today begins a new chapter for MindMaze Therapeutics,” he said. “Our mission is to transform neurological care and address a critical gap in motor and cognition restorations in neurological conditions.” The merger with NeuroX not only strengthens their growth strategy but also enhances opportunities for drug-digital integration.
MindMaze Therapeutics acquired NeuroX through a share exchange, where all outstanding shares of NeuroX were contributed by its former shareholders in exchange for 140,000,000 newly issued ordinary shares. These shares are now listed on the SIX Swiss Exchange under the ticker symbol MMTX. Following the transaction, the total number of outstanding shares amounts to 152,602,044, excluding treasury shares.
The company is dedicated to developing and commercializing innovative digital treatments for neurological diseases and is already deploying its solutions in clinical and home settings worldwide. MindMaze Therapeutics has shown promising results in conditions such as stroke, Parkinson’s disease, and cognitive decline related to aging.
In addition to its focus on neurological disorders, MindMaze Therapeutics also manages a portfolio of biopharmaceutical assets from Relief Therapeutics, targeting rare dermatological, metabolic, and respiratory diseases. This comprehensive approach positions the company for significant advancements in both digital and pharmacological therapies.
As MindMaze Therapeutics embarks on this new journey, it seeks to expand its research and development pipeline into additional neurological conditions, including multiple sclerosis, spinal cord injury, traumatic brain injury, and Alzheimer’s disease. The company is committed to delivering impactful solutions that improve the quality of life for patients facing these challenging conditions.
For further information, visit [www.mindmazetherapeutics.com](http://www.mindmazetherapeutics.com).
This release includes forward-looking statements based on current plans that may vary due to various risks and uncertainties. MindMaze Therapeutics does not undertake any obligation to update these statements following new information or events.
